DICERNA

The mark consists of DICERNA in stylized blue letters on a white background.

Mark For: DICERNA™ trademark registration is intended to cover the categories of research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. [all]

>The color(s) blue and white is/are claimed as a feature of the mark. The mark consists of DICERNA in stylized blue letters on a white background.

Status

2020-01-16 UTC
⟳ Refresh

LIVE APPLICATION Awaiting Examination

Research	OneLook Acronym Finder
Serial Number	88694416
Mark Literal Elements	DICERNA
Mark Drawing Type	5 - AN ILLUSTRATION DRAWING WITH WORD(S) /LETTER(S)/ NUMBER(S) INSTYLIZED FORM
Mark Type	TRADEMARK. SERVICE MARK
Standard Character Claim	No
Register	PRINCIPAL
Current Location	NEW APPLICATION PROCESSING 2019-11-21
Basis	1(b)
Class Status	ACTIVE
Primary US Classes	100: Miscellaneous 101: Advertising and Business
Primary International Class	042 - Primary Class (Computer, scientific & legal) Scientific and technological services and research and design relating thereto: industrial analysis and research services; design and development of computer hardware and software; legal services.
Filed Use	No
Current Use	No
Intent To Use	Yes
Filed ITU	Yes
44D Filed	No
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Attorney Name	Glenn A. Gundersen
Attorney Docket Number	166233-038

Timeline

IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
IC 042. US 100 101. G & S: Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials